佐力药业前脚再融资后脚抛并购，未来医药资产组觅得A股新买家

Core Viewpoint - Zhaoli Pharmaceutical plans to acquire a variety of trace element injection assets from Future Pharmaceutical for 356 million yuan, aiming to optimize its product structure and expand its treatment areas, despite a 6.22% drop in stock price following the announcement [1][6]. Group 1: Acquisition Details - The acquisition includes the purchase of "Multiple Trace Element Injection (I)", "Multiple Trace Element Injection (II)", and the in-development "Multiple Trace Element Injection (III)", along with associated technical data, licenses, trademarks, and employee relations [4][5]. - The acquisition price of 356 million yuan is significantly lower than the previous offer of up to 480 million yuan made by Nanxin Pharmaceutical, indicating a market-driven adjustment in asset valuation [1][8]. Group 2: Financial Context - Zhaoli Pharmaceutical recently announced a fundraising plan to issue convertible bonds totaling 1.556 billion yuan, with 250 million yuan allocated for working capital [10]. - The assets to be acquired generated a net profit of approximately 45.79 million yuan from January to September this year, indicating strong profitability [8]. Group 3: Market Reaction and Future Outlook - Following the acquisition announcement, Zhaoli Pharmaceutical's stock fell by 6.22%, closing at 17.18 yuan per share, reflecting investor sentiment regarding the deal [6]. - The success of the acquisition in enhancing product structure and profitability will depend on effective asset integration and market expansion execution [12].